PEJ: Assign numbers to outcomes to track hospital performance

tracking, business - 88.45 Kb
Assigning a numerical value to an outcome can objectify the healthcare processes and lead to a clearer understanding of how and when high-quality care is provided, according to an article published in the March/April edition of Physician Executive Journal of Medical Management.

“The backbone of the concept of quality is defining care that is appropriate,” wrote Peter L. Duffy, MD, from Pinehurst Cardiology Consultants in Pinehurst, N.C. “Inappropriate care has no quality.”

However, Duffy suggested that "appropriateness can be viewed as something that is suitable or proper for the circumstances," and went to define various levels to help categorize care:
  • All information suggests no benefit from intended action;
  • Most information indicates action is inappropriate and may cause harm;
  • Information is limited or suspect; and
  • Insufficient information exists to define this care as appropriate or not appropriate.

While some will argue that it isn’t fair to hold clinicians to outcome measures when assessing quality, others feel process measures are more reliable determinants of quality as they are easier to track, more objective and reproducible, Duffy acknowledged.

“However, … we in healthcare will be judged by the results we achieve, not by the level of effort we demonstrate,” he wrote. “Payors and patients alike will seek results and our systems must be geared to produce desired results, demonstrate that we do it and that we do it consistently.”

Duffy concluded by suggesting the following scale:
  • 6 – The outcome produced the intended result. No harm was done to the patient (safe), and the action had its intended consequence.
  • 5 – The outcome produced most of the intended result (90 percent or greater) with no harm to the patient.
  • 4 – The outcome produced some of the intended result (50-90 percent) with no harm to the patient.
  • 3 – The outcome produced harm to the patient that was unavoidable due to the clinical condition of the patient.
  • 2 – The outcome produced only some of the expected result with no harm to the patient.
  • 1 – The outcome resulted in minor unexpected harm to the patient.
  • 0 – The outcome resulted in major unexpected harm to the patient.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.